

Impact of P-glycoprotein-mediated active efflux on drug distribution into lumbar cerebrospinal fluid  
in nonhuman primates

Yoko Nagaya, Kazuhide Katayama, Hiroyuki Kusuhara, and Yoshitane Nozaki

Drug Metabolism and Pharmacokinetics Tsukuba, Biopharmaceutical Assessments Core Function  
Unit, Eisai Co., Ltd., Ibaraki, Japan (YNa, YNo)

Exploratory Group, DMPK&Bioanalysis Unit, Tsukuba R&D Supporting Division, Sunplanet Co.,  
Ltd., Ibaraki, Japan (KK)

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The  
University of Tokyo, Tokyo, Japan (HK)

\*YNa and YNo equally contributed to this work.

Running title: Distribution of P-gp substrates into lumbar CSF in monkeys

Address correspondence to

Yoko Nagaya, Ph.D.

Drug Metabolism and Pharmacokinetics Tsukuba, Biopharmaceutical Assessments Core Function  
Unit, Eisai Co., Ltd., 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan

Telephone: +81-29-847-5711

Fax: +81-29-847-5672

E-mail: y-nagaya@hhc.eisai.co.jp

Number of Text Pages: 33

Number of Tables: 2

Number of Figures: 6

Number of References: 32

Number of Abstract: 247 words

Number of Introduction: 749 words

Number of Discussion: 1437 words

## Abstract

Estimation of unbound drug concentration in the brain ( $C_{u,brain}$ ) is an essential part of central nervous system (CNS) drug development. As a surrogate for  $C_{u,brain}$  in humans and nonhuman primates, drug concentration in the cerebrospinal fluid ( $C_{CSF}$ ) collected by lumbar puncture is often used; however, the predictability of  $C_{u,brain}$  by lumbar  $C_{CSF}$  is unclear, particularly for substrates of the active efflux transporter P-glycoprotein (P-gp). Here, we measured lumbar  $C_{CSF}$  in cynomolgus monkey after single intravenous administration of 10 test compounds with varying P-gp transport activities. The *in vivo* lumbar CSF-to-plasma unbound drug concentration ratios ( $K_{p,uu,lumbar\ CSF}$ ) of nonsubstrates or weak substrates of P-gp were in the range 0.885–1.34, whereas those of good substrates of P-gp were in the range 0.195–0.458, and were strongly negatively correlated with *in vitro* P-gp transport activity. Moreover, concomitant treatment with a P-gp inhibitor, zosuquidar, increased the  $K_{p,uu,lumbar\ CSF}$  values of the good P-gp substrates, indicating that P-gp-mediated active efflux contributed to the low  $K_{p,uu,lumbar\ CSF}$  values of these compounds. Compared with the drug concentrations in the cisternal CSF and interstitial fluid (ISF) that we previously determined in cynomolgus monkeys, the lumbar  $C_{CSF}$  were more than triple for 2 and all of the good P-gp substrates examined, respectively. Although lumbar  $C_{CSF}$  may overestimate cisternal CSF and ISF concentrations of good P-gp substrates, lumbar  $C_{CSF}$  allowed discrimination of good P-gp substrates from the weak and nonsubstrates and can be used to estimate the impact of P-gp-mediated active efflux on drug CNS penetration.

## Significance Statement

This is the first study to systematically evaluate the penetration of various P-gp substrates into lumbar CSF in nonhuman primates. Lumbar CSF may contain >3-fold higher concentrations of good P-gp substrates than ISF and cisternal CSF, but was able to discriminate the good substrates from the weak or nonsubstrates. Because lumbar CSF is more accessible than ISF and cisternal CSF in

nonhuman primates, these findings will help increase our understanding of drug CNS penetration at the nonclinical stage.

## Abbreviations

AUC, area under the plasma concentration time-curve; BAB, blood–arachnoid barrier; BBB, blood–brain barrier; BCRP, breast cancer resistance protein;  $C_{\text{CSF}}$ , drug concentration in CSF; CER, corrected efflux ratio;  $C_{\text{ISF}}$ , drug concentration in interstitial fluid; CNS, central nervous system; CSF, cerebrospinal fluid; DCPQ, (2*R*)-anti-5-{3-[4-(10,11-dichloromethanodibenzo-suber-5-yl)piperazin-1-yl]-2-hydroxy-propoxy}quinolone trihydrochloride; E2074, 2-[(2*R*)-2-Fluoro-3-[(3*r*)-[(3-fluorobenzyl)oxy]-8-azabicyclo[3.2.1]oct-8-yl]propyl]-4,5-dimethyl-2,4-dihydro-3*H*-1,2,4-triazol-3-one; ER, efflux ratio; ISF, interstitial fluid; P-gp, P-glycoprotein; PhIP, 2-Amino-1-methyl-6-phenylimidazo(4,5-*b*)pyridine; PK/PD, pharmacokinetics/pharmacodynamics.

## Introduction

Ensuring that drugs reach their target in the central nervous system (CNS) at appropriate concentrations is an important part of CNS drug development. The CNS is protected by blood–tissue barriers, such as the blood–brain barrier (BBB), which are characterized by highly developed tight junctions and active efflux transporters, such as P-glycoprotein (P-gp), that act to prevent or reduce exposure of the CNS to drugs and other xenobiotics (Urquhart and Kim, 2009). Active efflux by these transporters reduces the unbound concentration of their substrates in the brain ( $C_{u,brain}$ ), which in turn reduces the effects of these substrates on the CNS (Xie et al., 1999; Zong and Pollack, 2000). This means that high doses are required for active efflux transporter substrates to attain an efficacious concentration, resulting in higher systemic exposure, and a narrower therapeutic index with respect to peripheral toxicities. The unbound concentration of such drugs in the plasma ( $C_{u,plasma}$ ) is no longer considered an appropriate biomarker of  $C_{u,brain}$  in understanding of the pharmacokinetics/pharmacodynamics (PK/PD) relationship of CNS-active compounds (Watson et al., 2009; Kanamitsu et al., 2016). Therefore, methods to quantitatively determine  $C_{u,brain}$  are required.

Determination of drug concentrations in the brain interstitial fluid ( $C_{ISF}$ ) by microdialysis (Benveniste and Huttemeier, 1990) is a direct approach to estimate  $C_{u,brain}$ ; however, due to its low throughput and technical difficulties, this technique is rarely used in drug development. Instead, the concentration of drug in the cerebrospinal fluid ( $C_{CSF}$ ) collected from the cisterna magna (the fourth ventricle) is used as a surrogate for  $C_{u,brain}$ , since the CSF is in close contact with the CNS, separated only by a layer of ependymal cells, which do not have a barrier function (Liu et al., 2006; Kodaira et al., 2011). Indeed, we have reported that for a set of compounds with high passive diffusion permeabilities and varying P-gp transport activities, in rats and monkeys, the cisternal  $C_{CSF}$  was within or close to triple the  $C_{ISF}$  (Nagaya et al., 2014; Nagaya et al., 2016).

Microdialysis and cisternal CSF sampling can provide a reliable estimate of  $C_{u,brain}$ ; however, they are highly invasive, requiring surgery for implanting catheters or microdialysis probes

in nonhuman primates and humans. Lumbar puncture is another technique often used to collect CSF samples, which is less invasive and applicable to healthy volunteers. Because drugs in the fourth ventricle are considered to diffuse into the ventricular space surrounding the spinal cord by bulk flow, no gradient between lumbar  $C_{CSF}$  and cisternal  $C_{CSF}$  is generally assumed. However, regional differences in the drug concentration in the CNS are a major concern when the pharmacological target site (e.g., cerebrum) is located far from the site of lumbar puncture. Indeed, differences in the  $C_{CSF}$  between cisternal and lumbar sites have been reported for some compounds (Strong et al., 1986; Blaney et al., 1995; Baker et al., 1996). Moreover, drug transporters in the arachnoid mater, under which the CSF flows, could modulate drug concentrations in the ventricles (Zhang et al., 2018). These findings cast doubt on the suitability of using lumbar  $C_{CSF}$  as a surrogate of  $C_{u,brain}$ , prompting us to systematically evaluate lumbar  $C_{CSF}$  of drugs that are transported by P-gp.

In the present study, a set of compounds with high passive diffusion membrane permeabilities and varying P-gp transport activities were intravenously administered to cynomolgus monkeys, and CSF was collected by lumbar puncture to measure lumbar  $C_{CSF}$ . Cynomolgus monkeys were used because the expression levels of P-gp in their BBB is similar to that in humans (Ito et al., 2011; Uchida et al., 2011). To evaluate the impact of P-gp on drug CNS penetration in monkeys, the effect of a P-gp inhibitor (zosuquidar) was also tested *in vivo*. For this purpose, DCPQ, cyclosporine A, tariquidar, elacridar, and PSC833 were previously used in the positron emission tomography studies (Kurdziel et al., 2003; Lee et al., 2006; Zoghbi et al., 2008; Eyal et al., 2009; Tournier et al., 2017) where the observation time period was relatively short (at most 4 h after administration). Dosing schedule of zosuquidar was established in this study to achieve potent P-gp inhibition over 24 h. Finally, the lumbar  $C_{CSF}$  values obtained in the present study were compared with  $C_{ISF}$  and cisternal  $C_{CSF}$  values that we previously determined (Nagaya et al., 2014) to gain an insight into the regional differences of drug concentrations in the CNS. This is the first study to systematically evaluate the penetration of various P-gp substrates into lumbar CSF in nonhuman primates and the suitability of using lumbar  $C_{CSF}$  as a surrogate of  $C_{u,brain}$ .

## Materials and Methods

### Chemicals.

Antipyrine, carbamazepine, propranolol hydrochloride, quinidine hydrochloride, and verapamil hydrochloride were purchased from Sigma Aldrich (St. Louis, MO). Desloratadine and ondansetron hydrochloride dehydrate were obtained from LKT Laboratories (St Paul, MN) and Tokyo Chemical Industry (Tokyo, Japan), respectively. Risperidone and paliperidone were purchased from AK scientific (Union City, CA), and zosuquidar hydrochloride was from Cayman Chemical (Ann Arbor, MI). A proprietary compound, E2074 (Nagaya et al., 2013) synthesized in Tsukuba Research Laboratories, Eisai Co., Ltd. (Ibaraki, Japan) was used. All other reagents and solvents were of analytical grade and commercially available.

### Animal experiments.

All experimental protocols and procedures were approved by the Institutional Animal Care and Use Committee of Eisai, and animal experiments were performed in Eisai Tsukuba Research Laboratories (Ibaraki, Japan) which was accredited by Japan Health Sciences Foundation (Tokyo, Japan). All efforts were made to minimize suffering. Six male cynomolgus monkeys (4–6 years old, 3–5 kg) were used in this study. The *in vivo* study consisted of two parts. In Part 1, single intravenous bolus dose of E2074 (1 mg/kg), carbamazepine (3 mg/kg), lamotrigine (3 mg/kg), ondansetron (3 mg/kg), verapamil (3 mg/kg), desloratadine (3 mg/kg), quinidine (5 mg/kg), or risperidone (0.5 mg/kg) was given to monkeys (n=3) via the saphenous vein to measure the drug concentrations in plasma and lumbar CSF up to 24 h postdose. To see inter-day variabilities in the monkey PK, antipyrine (1 mg/kg) was intravenously administered to monkeys concomitantly with each of the test compounds. No considerable inter-day variabilities were observed in the PK of antipyrine. Paliperidone (an active metabolite of risperidone) was not directly administered to



monkeys, but was quantified in plasma and lumbar CSF after risperidone administration. The same animals were repeatedly used with at least 3-week washout period between doses in Part 1, allowing the animals to fully recover from lumbar puncture and CSF loss. In Part 2, the effect of a P-gp inhibitor (zosuquidar) on the CNS penetration of test compounds was examined in monkeys. An intravenous bolus dose of zosuquidar (10 mg/kg) or vehicle (DMSO/5% glucose, 5/95, v/v) was given to monkeys (n=3) via the saphenous vein. Ten minutes later, a cocktail of 4 test compounds (antipyrine, ondansetron, desloratadine, and quinidine) was intravenously given to the animals as a single dose via the saphenous vein with the same dose levels as used in Part 1. At 8 h after the first zosuquidar administration, zosuquidar (10 mg/kg) was intravenously administered again to maintain the inhibitory effect on P-gp for 24 h. The same animals were used for zosuquidar and vehicle treatments in Part 2, and 1-month washout period was allocated between doses.

In Parts 1 and 2, blood (0.5 mL per sampling point) was collected via cephalic vein, and CSF (0.1 mL per sampling point) was collected by lumbar puncture at 2, 6, and 24 h postdose of the test compounds. For lumbar CSF collection, animals were anesthetized with intramuscular administration of ketamine (5 mg/kg) and xylazine (1 mg/kg) immediately before each timepoint, and the lumbar puncture site was swabbed with povidone-iodine containing disinfectant. Lumbar CSF was collected at the L3 to L6 intervertebral space in a flexed position, and then the site was swabbed again with the disinfectant. The blood samples were centrifuged to prepare plasma. The plasma and CSF samples were stored below  $-20^{\circ}\text{C}$  until analysis.

#### **In vitro transcellular transport study using P-gp-expressing and control cell monolayers.**

The inhibitory effect of zosuquidar on P-gp-mediated transcellular transport of desloratadine and quinidine was evaluated using human P-gp-expressing LLC-PK1 and control LLC-PK1 cells (Corning Inc., Corning, NY). The cells were seeded at  $6 \times 10^5$  cells/cm<sup>2</sup> in a cell culture insert (HTS Transwell<sup>®</sup>-24-well permeable support with 0.4  $\mu\text{m}$  pore polyester membrane

and 6.5 mm inserts; Corning Inc., Corning, NY) and cultured for 5 days. Then, the medium in the apical and basal sides was replaced with Hanks' Balanced Salt solution (HBSS) containing 10 mmol/L HEPES (HBSS/HEPES) and zosuquidar (0–1  $\mu\text{mol/L}$ ). After 2-h preincubation at 37 °C, the receiver-side solution was replaced with HBSS/HEPES containing zosuquidar, and the donor-side solution was replaced with HBSS/HEPES containing zosuquidar (0–1  $\mu\text{mol/L}$ ) and desloratadine (0.3  $\mu\text{mol/L}$ ) or quinidine (0.3  $\mu\text{mol/L}$ ). The cells were incubated at 37 °C for 2 h, and a 40  $\mu\text{L}$  aliquot of the receiver-side solution was collected and stored below –20 °C until analysis. The transcellular transport of paliperidone (1  $\mu\text{mol/L}$ ) was also evaluated in the same manner, using HBSS/HEPES without zosuquidar.

#### **Analytical procedure.**

In vivo samples (monkey plasma and CSF) were mixed with acetonitrile containing an internal standard (IS, 10 nmol/L propranolol) followed by centrifugation. The samples from in vitro P-gp transcellular transport study were mixed with methanol containing the IS and centrifuged. The resulting supernatant was filtrated, and an aliquot of the filtrate was subjected to high-performance liquid chromatography with tandem mass spectrometry analysis. Chromatography was performed using an ACQUITY UPLC CSH C18 column (1.7  $\mu\text{m}$ , 2.1 mm i.d.  $\times$  50 mm; Waters, Milford, MA) at a flow rate of 0.3 mL/min. Distilled water containing 0.02% or 0.1% formic acid (solvent A) and acetonitrile containing 0.02% or 0.1% formic acid (solvent B) were used as the mobile phases. The initial mobile phase was 100% solvent A, and the percentage of solvent B was linearly increased to 50% or 80% over 3 min. The column was equilibrated with the initial mobile phase before each injection. A Xevo TQ-S or Xevo TQ-XS mass spectrometer (Waters) was used for detection. Analytes were ionized by electrospray ionization in positive ion mode, and the selected ion monitoring transitions were: 189.0>76.7 for antipyrine, 237.3>193.6 for carbamazepine, 256.0>210.5 for lamotrigine, 294.1>169.8 for ondansetron, 407.3>172.0 for E2074, 411.2>190.7 for

risperidone, 427.4>207.4 for paliperidone, 455.2>164.8 for verapamil, 311.2>259.2 for desloratadine, 325.2>160.2 for quinidine, 260.1>115.9 for propranolol, and 528.5>241.1 for zosuquidar.

### Parameter calculations.

Unbound drug concentration in plasma ( $C_{u,plasma}$ ) was calculated by multiplying total plasma concentration ( $C_{plasma}$ ) by unbound fraction in plasma ( $f_{u,plasma}$ ). The  $f_{u,plasma}$  values of antipyrine (1.00), carbamazepine (0.366), lamotrigine (0.536), ondansetron (0.551), E2074 (0.676), paliperidone (0.308), risperidone (0.163), verapamil (0.328), desloratadine (0.142), and quinidine (0.156) were previously determined by an equilibrium dialysis method in blank plasma freshly-prepared from cynomolgus monkeys (Nagaya et al., 2014). The  $f_{u,plasma}$  of zosuquidar (0.00356) was also determined in the freshly-prepared monkey plasma by the equilibrium dialysis (RED device, 8K MWCO, Thermo Fisher Scientific, Waltham, MA) by a dilution method according to the previous study (Riccardi et al., 2015). In the present study, the lumbar CSF-to-unbound plasma AUC ratio ( $K_{p,uu,lumbar\ CSF}$ ) was calculated as an index for drug CNS penetration by the following equation.

$$K_{p,uu,lumbar\ CSF} = \frac{AUC_{CSF(2-24h)}}{f_{u,plasma} \times AUC_{plasma(2-24h)}}$$

The AUC of test compounds were calculated by a linear trapezoidal method from 2 to 24 h postdose for plasma ( $AUC_{plasma(2-24h)}$ ) and CSF ( $AUC_{CSF(2-24h)}$ ) using Excel 2016. Protein binding of the test compounds except for paliperidone was previously measured in the monkey CSF (Nagaya et al., 2014), and was found negligible (0%–13%); therefore, observed CSF concentrations were directly used for calculating  $AUC_{CSF(2-24h)}$  in this study. When the drug concentration in a sample obtained at 24 h postdose was below quantification limit, zero was used to calculate the AUC.

In the in vitro transcellular transport study, the efflux ratio (ER) was calculated from the ratio of the apparent permeability ( $P_{app}$ ) in basal-to-apical direction ( $P_{app,B-A}$ ) to that in apical-to-basal direction ( $P_{app,A-B}$ ) in the P-gp-expressing cells ( $ER_{P-gp}$ ) and control cells ( $ER_{Ctrl}$ ). The corrected efflux ratio (CER) was defined as follows:

$$CER = \frac{ER_{P-gp}}{ER_{Ctrl}}$$

In the in vitro P-gp inhibition study,  $ER_{P-gp}$  and  $ER_{Ctrl}$  were calculated for desloratadine and quinidine. The percentage of control values for P-gp-mediated transcellular transport of desloratadine and quinidine in the presence of zosuquidar were calculated from the ER values according to the following equation:

$$\% \text{ of control} = \frac{ER_{P-gp,ZOS(+)} - ER_{Ctrl,ZOS(+)}}{ER_{P-gp,ZOS(-)} - ER_{Ctrl,ZOS(-)}} \times 100$$

where  $ER_{P-gp,ZOS(+)}$  and  $ER_{Ctrl,ZOS(+)}$  represent  $ER_{P-gp}$  and  $ER_{Ctrl}$  determined in the presence of zosuquidar (0–1  $\mu\text{mol/L}$ ), respectively.  $ER_{P-gp,ZOS(-)}$  and  $ER_{Ctrl,ZOS(-)}$  represent  $ER_{P-gp}$  and  $ER_{Ctrl}$  determined in the absence of zosuquidar, respectively. According to the following equation, the  $IC_{50}$  value of zosuquidar was calculated from the relationship between zosuquidar concentrations ([I]) and the % of control by the nonlinear regression least squares method, using GraphPad Prism (ver. 8.0).

$$\% \text{ of control} = \frac{\text{Top}}{1 + \frac{[I]}{IC_{50}}}$$

The maximum % of control value in the absence of zosuquidar (Top) was set as a free parameter and estimated.

## Statistics.

Data are expressed as mean or mean  $\pm$  SD. Pearson correlation coefficient ( $r$ ) was computed to analyze the relationship between in vitro P-gp CER values and in vivo  $K_{p,uu,lumbar\ CSF}$  values. Paired  $t$  test was performed to identify significant difference in  $C_{CSF}/C_{u,plasma}$  at 24 h with and without zosuquidar [Supplemental table 2 (B)], and the differences was considered significant when  $P < 0.05$ . Statistical analysis was performed using GraphPad Prism Ver 8.0 (GraphPad Software, SanDiego, CA).

## Results

### Penetration of test compounds into lumbar CSF.

Based on their corrected efflux ratios (CERs), we classified the test compounds as nonsubstrates (CER < 2; antipyrine, carbamazepine, and lamotrigine), weak substrates (CER, 2–3; ondansetron and E2074), or good substrates of P-gp (CER > 3; paliperidone, risperidone, verapamil, desloratadine, and quinidine) according to our previous study (Nagaya et al., 2014). The CERs of nine of the test compounds were taken from that previous study, and that for paliperidone was determined in the present study under assay conditions identical to those used previously.

For all of the compounds,  $C_{\text{plasma}}$  and lumbar  $C_{\text{CSF}}$  decreased in parallel throughout the observation period, except for desloratadine for which lumbar  $C_{\text{CSF}}$  increased from 2 to 6 h after administration (Figure 1). For the nonsubstrates and weak substrates of P-gp throughout the observation period, the lumbar  $C_{\text{CSF}}$  was comparable with the  $C_{\text{u,plasma}}$  ( $K_{\text{p,uu,lumbar CSF}}$ , 0.885–1.34; Table 1), whereas for the good substrates, the lumbar  $C_{\text{CSF}}$  was lower than the  $C_{\text{u,plasma}}$  ( $K_{\text{p,uu,lumbar CSF}}$ , 0.195–0.458). All test compounds were well tolerated by the monkeys under the study conditions, although drowsiness was observed in all 3 animals treated with risperidone, but was fully resolved by 24 h postdose.

Figure 2 shows the *in vivo*  $K_{\text{p,uu,lumbar CSF}}$  values of the test compounds plotted against their *in vitro* P-gp CER values. A strong negative correlation ( $R^2 = 0.762$ ) was observed, in which a higher *in vitro* P-gp CER was associated with a lower *in vivo*  $K_{\text{p,uu,lumbar CSF}}$ .

### Effect of a P-gp inhibitor on the penetration of P-gp substrates into the lumbar CSF.

A cocktail of antipyrine (nonsubstrate), ondansetron (weak substrate), desloratadine (good substrate), and quinidine (good substrate) was intravenously administered to monkeys in the presence or absence of concomitant treatment with the P-gp inhibitor zosuquidar. The animals

received two intravenous bolus doses of zosuquidar (both 10 mg/kg), with the first given 10 min before the administration of the test compound cocktail and the second given 8 h later. In the zosuquidar treatment phase, convulsion was observed in one of the three animals shortly after administration of the test compound cocktail, and blood and lumbar CSF could not be collected at 2 h postdose from that animal. Thereafter, convulsion disappeared, and blood and CSF sampling (at 6 and 24 h postdose) and the second administration of zosuquidar were performed as scheduled for that animal without recurrence of convulsion.

Zosuquidar had no effect on the  $C_{u,plasma}$  of antipyrine, ondansetron, and quinidine, whereas it delayed the elimination of desloratadine from the systemic circulation (Figure 3). The  $C_{plasma}$  (and  $C_{u,plasma}$ ) of desloratadine at 24 h postdose with zosuquidar treatment was 1.8 times that without. Zosuquidar had no effect on the lumbar  $C_{CSF}$  of antipyrine, but slightly increased the lumbar  $C_{CSF}$  of ondansetron, with the  $K_{p,uu,lumbar\ CSF}$  increasing from 0.861 to 1.08 (Table 2). For desloratadine, zosuquidar increased the lumbar  $C_{CSF}$  and delayed the time to maximum concentration from 2 to 6 h postdose, resulting in an increase in  $K_{p,uu,lumbar\ CSF}$  from 0.151 to 0.250. For quinidine, the time profile of lumbar  $C_{CSF}$  completely matched that of  $C_{u,plasma}$  in the presence of zosuquidar, and the  $K_{p,uu,lumbar\ CSF}$  increased from 0.239 to 0.987. Thus, the effect of zosuquidar on lumbar  $C_{CSF}$  was more evident for desloratadine and quinidine than it was for antipyrine and ondansetron.

The  $C_{plasma}$ ,  $C_{u,plasma}$ , and  $C_{CSF}$  of zosuquidar were also measured in cynomolgus monkeys administered the test compound cocktail (Figure 4). The  $C_{u,plasma}$  of zosuquidar was 3.12, 0.954, and 0.218 ng/mL at 2, 6, and 24 h postdose of the test compound cocktail. The corresponding lumbar  $C_{CSF}$  of zosuquidar was 0.414, 0.376, and 0.230 ng/mL, respectively.

#### **Inhibition of P-gp by zosuquidar in vitro.**

The inhibitory effect of zosuquidar on human P-gp-mediated transport of desloratadine and quinidine was examined in vitro by using human P-gp-expressing cells (Figure 5 and Supplemental Table 1). The  $IC_{50}$  values (parameter estimate  $\pm$  parameter SD) of zosuquidar for P-gp-mediated transport of quinidine and desloratadine transport were  $5.38 \pm 0.67$  and  $3.46 \pm 0.35$  nmol/L (corresponding to 2.84 and 1.82 ng/mL), respectively.

#### **Comparison of $K_{p,uu,lumbar\ CSF}$ with $K_{p,uu,cisternal\ CSF}$ and $K_{p,uu,ISF}$ values.**

We compared the  $K_{p,uu,lumbar\ CSF}$  values of the test compounds obtained in the present study with the  $K_{p,uu,cisternal\ CSF}$  and  $K_{p,uu,ISF}$  values reported previously (Table 1 and Figure 6). The  $K_{p,uu,lumbar\ CSF}$  of the nonsubstrates (antipyrine, carbamazepine, and lamotrigine) were quite similar to the previous  $K_{p,uu,cisternal\ CSF}$  and  $K_{p,uu,ISF}$  values. The  $K_{p,uu,lumbar\ CSF}$  of the weak P-gp substrates (ondansetron and E2074) were slightly greater than the previous  $K_{p,uu,cisternal\ CSF}$  and  $K_{p,uu,ISF}$  values, but by less than a factor of 3. The  $K_{p,uu,lumbar\ CSF}$  of the good P-gp substrates (paliperidone, risperidone, verapamil, desloratadine, and quinidine) were more than triple the previous  $K_{p,uu,cisternal\ CSF}$  and  $K_{p,uu,ISF}$  values. The  $K_{p,uu,lumbar\ CSF}:K_{p,uu,cisternal\ CSF}$  ratio of paliperidone was 4.6 and that of risperidone 3.4. The  $K_{p,uu,lumbar\ CSF}:K_{p,uu,ISF}$  of all of the good substrates examined was 3.2 to 5.1.



## Discussion

Lumbar puncture is a widely used means of collecting CSF to obtain an estimate of  $C_{u,brain}$  of drugs in nonhuman primates and humans; however, the predictability of  $C_{u,brain}$  by lumbar  $C_{CSF}$  has not been systematically evaluated, particularly for P-gp substrates. In the present study, penetration into the lumbar CSF of 10 compounds with high passive diffusion membrane permeabilities and varying P-gp transport activities was examined in cynomolgus monkeys. Since sampling of the cisternal CSF could affect the downstream spinal CSF flow, only lumbar CSF was sampled in the present study and the data obtained were compared with  $C_{ISF}$  and cisternal  $C_{CSF}$  data we reported previously (Nagaya et al., 2014).

After intravenous administration of a single dose, the lumbar  $C_{CSF}$  quickly reached a pseudosteady state for all the test compounds except for desloratadine (Figure 1). The lumbar  $C_{CSF}$  to  $C_{u,plasma}$  ratio at a given sampling time point provides a reliable estimate of  $K_{p,uu,lumbar\ CSF}$  (Supplemental Table 2), which would be useful to mitigate the stress of repeated lumbar punctures in animals by avoiding the need for sampling at multiple time points. The strong brain tissue binding of desloratadine, as compared to other test drugs (Nagaya et al., 2014), likely accounts for the slower distribution of desloratadine into lumbar CSF. Furthermore, the  $K_{p,uu,lumbar\ CSF}$  decreased with increasing P-gp activity, allowing discrimination of good P-gp substrates (paliperidone, risperidone, verapamil, desloratadine, and quinidine) from the nonsubstrates (antipyrine, carbamazepine, and lamotrigine) and weak substrates (ondansetron and E2074) of P-gp (Figure 2), which is consistent with our previous observations for  $K_{p,uu,ISF}$  and  $K_{p,uu,cisternal\ CSF}$  (Nagaya et al., 2016).

We then examined the effect of zosuquidar, a P-gp inhibitor, on the  $K_{p,uu,lumbar\ CSF}$  using a cocktail of antipyrine, ondansetron, desloratadine, and quinidine, to confirm that the  $K_{p,uu,lumbar\ CSF}$  is indeed related to the P-gp activity. The reported plasma concentration threshold to increase the brain-to-plasma total drug concentration ratio of P-gp substrates is 0.3–0.4  $\mu\text{g/mL}$  in rats (Anderson et al., 2006). Based on the single-dose pharmacokinetic profile of zosuquidar in cynomolgus monkey

(Supplemental Figure 1), a 10 mg/kg intravenous bolus dose of zosuquidar was given twice during a 24-h period. This dosing regimen was projected to achieve a mean zosuquidar plasma concentration of 0.83  $\mu\text{g/mL}$  for 24 h, which was greater than the plasma concentration threshold in rats. Although the observed  $C_{u,\text{plasma}}$  of zosuquidar (0.4–5.9 nmol/L, Figure 4) over the 24-h observation period was similar to or lower than the *in vitro*  $\text{IC}_{50}$  values of zosuquidar against P-gp (3.5–5.4 nmol/L) (Figure 5), the  $K_{p,\text{uu,lumbar CSF}}$  values of the P-gp substrates ondansetron, desloratadine, and quinidine were increased by 1.3-, 1.7-, and 4.1-fold, respectively, being close to unity for ondansetron (1.1) and quinidine (0.99) (Table 2 and Supplemental Table 2). The absence of change of the  $K_{p,\text{uu,lumbar CSF}}$  of antipyrine (nonsubstrate) excluded the possibility of a non-selective effect of zosuquidar on the barrier function. Thus, we contend that the zosuquidar dosing regimen presented in this study adequately inhibited P-gp in the CNS, and that the  $K_{p,\text{uu,lumbar CSF}}$  is a useful surrogate index for quantitative assessment of P-gp in the barrier of CNS. It is also noteworthy that the  $K_{p,\text{uu,lumbar CSF}}$  value of each test compound after the cocktail dosing (Table 2) was consistent with that determined with antipyrine (Table 1), and antipyrine did not alter the CNS penetration of good P-gp substrates (risperidone and paliperidone) in rats (data not shown). Therefore, it is unlikely that drug-drug interactions via P-gp occurred in the CNS after the cocktail dosing.

The *in vitro* P-gp CERs of desloratadine and quinidine were comparable (12 and 13, respectively) (Table 1), resulting in similar  $K_{p,\text{uu,lumbar CSF}}$  values (Figure 2); nevertheless, the degree of the increase of  $K_{p,\text{uu,lumbar CSF}}$  by zosuquidar was modest for desloratadine. We confirmed that the  $\text{IC}_{50}$  values of zosuquidar against human P-gp-mediated transport of desloratadine (3.5 nmol/L) and quinidine (5.4 nmol/L) were similar *in vitro* (Figure 5), thereby excluding the possibility of substrate-dependent inhibition, as reported for other transporters (Nozaki and Izumi, 2020). Given that human and monkey P-gp show 96% amino acid sequence homology and are well correlated with respect to their *in vitro* transport activities (Takeuchi et al., 2006; Kim et al., 2008), the  $\text{IC}_{50}$  values of zosuquidar for P-gp in the monkey is unlikely to show any remarkable substrate dependence. There are two possibilities. In addition to P-gp, other transporter(s) could also mediate

the active efflux of desloratadine from the CNS. However, breast cancer resistance protein (BCRP), a well-characterized efflux transporter in the BBB, did not accept desloratadine (CER = 0.81) as a substrate in human BCRP-expressing MDCKII cells (CER of PhIP as a positive control substrate, 14.78). Another possibility is that the lumbar  $C_{CSF}$  might not reach the pseudosteady state by 24 h because of the extremely low unbound fraction in the brain (Nagaya et al., 2014).

During co-treatment with zosuquidar and the test compound cocktail, convulsion occurred in one of the three animals shortly after administration of the cocktail. Since convulsion did not recur after the second dose of zosuquidar in the same animal, this suggests that one or more of the compounds in the test cocktail were the cause of the convulsions. Of the compounds included in the cocktail, quinidine and desloratadine are reported to elicit convulsions in humans (Kerr et al., 1971; Cerminara et al., 2013) and zosuquidar increased the lumbar  $C_{CSF}$  of these compounds.

Regional differences in the drug concentrations in the CNS are a potential concern when using lumbar puncture to estimate  $C_{u,brain}$ . Indeed, the AUC of lamivudine in lumbar CSF was 5.5 times that in ventricular CSF in rhesus monkeys (Blaney et al., 1995). Conversely, in children, the CSF penetration of topotecan into the lumbar space was significantly lower than that into the ventricular space (Baker et al., 1996). The reported exposure to thiotepa is equal between the lumbar and ventricular CSF in rhesus monkeys (Strong et al., 1986). To provide more information in this context, we compared the  $K_{p,uu,lumbar\ CSF}$  values obtained in the present study with the  $K_{p,uu,ISF}$  (Figure 6A) and  $K_{p,uu,cisternal\ CSF}$  values (Figure 6B) determined under steady-state conditions in cynomolgus monkeys in our previous study (Nagaya et al., 2014). The  $K_{p,uu,ISF}$  and  $K_{p,uu,cisternal\ CSF}$  values of the nonsubstrates and weak substrates of P-gp were within a factor of 3 of the corresponding  $K_{p,uu,lumbar\ CSF}$  values. Therefore, the lumbar  $C_{CSF}$  can be used as a surrogate of  $C_{ISF}$  for new chemical entities (NCEs) with high passive permeability that are not/only weakly transported by P-gp. In contrast, the  $K_{p,uu,lumbar\ CSF}$  values of the good substrates were more than triple the corresponding  $K_{p,uu,ISF}$  values.  $K_{p,uu,cisternal\ CSF}$  originally tended to overestimate  $K_{p,uu,ISF}$  of the good substrates

(Nagaya et al., 2014), and collection of CSF from downstream of the flow (lumbar puncture) further increased the gap by 2- to 3-fold (Table 1). Although such regional concentration differences can be a limiting factor in the precise estimation of  $C_{u,brain}$ , the lumbar  $C_{CSF}$  allowed discrimination of good P-gp substrates from weak and nonsubstrates (Figure 2). Taking into consideration the easy accessibility and lower burden to the experimental animals, lumbar  $C_{CSF}$  can be used for compound prioritization in the nonclinical stages. When investigators focus on good P-gp substrates and 3- to 5-fold overestimation given by lumbar  $C_{CSF}$  is not acceptable, microdialysis or cisternal CSF sampling will be a better option.

The reason for the increasing cerebral–cisternal–lumbar concentration gradient observed for the good P-gp substrates is unknown. Whether choroid plexus epithelial cells, which show weak P-gp expression but are on the side facing the CSF (Rao et al., 1999), are able to extrude P-gp substrates into the ventricles remains unknown. Lumbar CSF is surrounded by the blood–arachnoid barrier (BAB), with P-gp expression demonstrated on the dura side of the membrane in rats and pigs (Yasuda et al., 2013; Uchida et al., 2020). If the expression of P-gp in the BAB is not as high as that in the BBB, the penetration of P-gp substrates from the systemic circulation would gradually increase from the ventricles to the spinal subarachnoid space. Further studies are needed to determine the lumbar  $C_{CSF}$  and  $C_{ISF}$  of other P-gp substrates as data for use in a regression analysis to examine the concentration gradient.

In conclusion, this study demonstrated the usefulness of lumbar  $C_{CSF}$  as a quantitative surrogate of  $C_{ISF}$  for non-substrate, weak to good substrates of P-gp. Lumbar CSF may contain >3-fold higher concentrations of good P-gp substrates than the ISF or cisternal CSF, but it was still possible to discriminate between good P-gp substrates and weak substrates/nonsubstrates. These findings will help lead optimization and drug candidate selection in the nonclinical phase of CNS drug development.

### **Acknowledgments.**

We would like to thank Tsugio Nakayama, Kenichi Kikuta, Katsuhiko Otsuka, Norio Fukuda, and Yosuke Nojiri (Sunplanet Co., Ltd, Tsukuba, Japan) for the technical assistance in the in vivo experiments.

**Authorship Contributions.**

Participated in research design: Nagaya, Kusuhara, Nozaki.

Conducted experiments: Nagaya, Katayama.

Contributed new reagents or analytic tools: Not applicable.

Performed data analysis: Nagaya, Nozaki.

Wrote or contributed to the writing of the manuscript: Nagaya, Kusuhara, Nozaki.

## References

- Anderson BD, May MJ, Jordan S, Song L, Roberts MJ, and Leggas M (2006) Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. *Drug Metab Dispos* **34**:653-659.
- Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, and Stewart CF (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. *Cancer Chemother Pharmacol* **37**:195-202.
- Benveniste H and Huttemeier PC (1990) Microdialysis--theory and application. *Prog Neurobiol* **35**:195-215.
- Blaney SM, Daniel MJ, Harker AJ, Godwin K, and Balis FM (1995) Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. *Antimicrob Agents Chemother* **39**:2779-2782.
- Cerminara C, El-Malhany N, Roberto D, Lo Castro A, and Curatolo P (2013) Seizures induced by desloratadine, a second-generation antihistamine: clinical observations. *Neuropediatrics* **44**:222-224.
- Eyal S, Chung FS, Muzi M, Link JM, Mankoff DA, Kaddoumi A, O'Sullivan F, Hebert MF, and Unadkat JD (2009) Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate. *J Nucl Med* **50**:798-806.
- Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, Kamiie J, and Terasaki T (2011) Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. *J Pharm Sci* **100**:3939-3950.
- Kanamitsu K, Arakawa R, Sugiyama Y, Suhara T, and Kusuhara H (2016) Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in vitro experiments.

*Drug Metab Pharmacokinet* **31**:395-404.

Kerr F, Kenoyer G, and Bilitch M (1971) Quinidine overdose. Neurological and cardiovascular toxicity in a normal person. *Br Heart J* **33**:629-631.

Kim IW, Booth-Genthe C, and Ambudkar SV (2008) Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1). *Mini Rev Med Chem* **8**:193-200.

Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, and Sugiyama Y (2011) Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. *J Pharmacol Exp Ther* **339**:935-944.

Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, and Herscovitch P (2003) Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. *J Nucl Med* **44**:1330-1339.

Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, Obayashi S, Nakao R, Suzuki K, Sugiyama Y, and Suhara T (2006) In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. *J Pharmacol Exp Ther* **316**:647-653.

Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, and Van Deusen J (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. *Drug Metab Dispos* **34**:1443-1447.

Nagaya Y, Nozaki Y, Kobayashi K, Takenaka O, Nakatani Y, Kusano K, Yoshimura T, and Kusuhara H (2014) Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates. *Drug Metab Pharmacokinet* **29**:419-426.



- Nagaya Y, Nozaki Y, Takenaka O, Watari R, Kusano K, Yoshimura T, and Kusuhara H (2016) Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats. *Drug Metab Pharmacokinet* **31**:57-66.
- Nagaya Y, Takenaka O, Kusano K, and Yoshimura T (2013) Species difference in the mechanism of nonlinear pharmacokinetics of E2074, a novel sodium channel inhibitor, in rats, dogs, and monkeys. *Drug Metab Dispos* **41**:1004-1011.
- Nozaki Y and Izumi S (2020) Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters. *Drug Metab Pharmacokinet* **35**:56-70.
- Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, and Piwnica-Worms D (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. *Proc Natl Acad Sci U S A* **96**:3900-3905.
- Riccardi K, Cawley S, Yates PD, Chang C, Funk C, Niosi M, Lin J, and Di L (2015) Plasma Protein Binding of Challenging Compounds. *J Pharm Sci* **104**:2627-2636.
- Strong JM, Collins JM, Lester C, and Poplack DG (1986) Pharmacokinetics of intraventricular and intravenous N,N',N"-triethylenethiophosphoramidate (thiotepa) in rhesus monkeys and humans. *Cancer Res* **46**:6101-6104.
- Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, Katoh M, Yokoi T, and Asahi S (2006) Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. *Pharm Res* **23**:1460-1472.
- Tournier N, Goutal S, Auvity S, Traxl A, Mairinger S, Wanek T, Helal OB, Buvat I, Soussan M,

- Caillé F, and Langer O (2017) Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates. *J Nucl Med* **58**:117-122.
- Uchida Y, Goto R, Takeuchi H, Łuczak M, Usui T, Tachikawa M, and Terasaki T (2020) Abundant Expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT Transporters in Blood-Arachnoid Barrier of Pig and Polarized Localizations at CSF- and Blood-Facing Plasma Membranes. *Drug Metab Dispos* **48**:135-145.
- Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. *J Neurochem* **117**:333-345.
- Urquhart BL and Kim RB (2009) Blood-brain barrier transporters and response to CNS-active drugs. *Eur J Clin Pharmacol* **65**:1063-1070.
- Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, and Read KD (2009) Receptor occupancy and brain free fraction. *Drug Metab Dispos* **37**:753-760.
- Xie R, Hammarlund-Udenaes M, de Boer AG, and de Lange EC (1999) The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in *mdr1a* (-/-) and *mdr1a* (+/+) mice. *Br J Pharmacol* **128**:563-568.
- Yasuda K, Cline C, Vogel P, Onciu M, Fatima S, Sorrentino BP, Thirumaran RK, Ekins S, Urade Y, Fujimori K, and Schuetz EG (2013) Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier. *Drug Metab Dispos* **41**:923-931.
- Zhang Z, Tachikawa M, Uchida Y, and Terasaki T (2018) Drug Clearance from Cerebrospinal Fluid Mediated by Organic Anion Transporters 1 (Slc22a6) and 3 (Slc22a8) at Arachnoid Membrane of Rats. *Mol Pharm* **15**:911-922.

Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, Gladding RL, Pike VW, and Innis RB  
(2008) 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. *J Nucl Med* **49**:649-656.

Zong J and Pollack GM (2000) Morphine antinociception is enhanced in mdr1a gene-deficient mice.  
*Pharm Res* **17**:749-753.

## Footnotes

This work received no external funding.

## Figure Legends

**Figure 1.** Total plasma (black solid lines with closed circles), unbound plasma (gray solid line with closed circles), and lumbar CSF (dotted line with open circles) concentration-time profiles of antipyrine (1 mg/kg), carbamazepine (3 mg/kg), lamotrigine (3 mg/kg), ondansetron (3 mg/kg), E2074 (1 mg/kg), paliperidone, risperidone (0.5 mg/kg), verapamil (3 mg/kg), desloratadine (3 mg/kg), and quinidine (5 mg/kg) after single intravenous administration in cynomolgus monkey. Paliperidone, an active metabolite of risperidone, was quantified after risperidone dosing. Blood and lumbar CSF were serially collected at 2, 6, and 24 h postdose. Each point represents the mean  $\pm$  SD of three animals, except for lumbar CSF concentration of risperidone at 24 h (n=1, below quantification limit in the other two animals). Since antipyrine was administered concomitantly with each of the test compounds, representative data are presented.

**Figure 2.** Relationship between in vitro human P-gp corrected efflux ratio (CER) and the  $K_{p,uu,lumbar\ CSF}$  in cynomolgus monkey.  $K_{p,uu,lumbar\ CSF}$  is presented as the mean  $\pm$  SD of three animals. The CER values (mean of triplicate or quadruplicate determinations) of test compounds except for paliperidone were obtained from our previous study (Nagaya et al., 2014), and that of paliperidone (1  $\mu$ mol/L) was determined in the present study as described under Materials and Methods. The test compounds were classified into nonsubstrates (CER < 2; open circles), weak substrates (CER, 2 – 3; gray circles), or good substrates of P-gp (CER > 3; closed circles) according to the previous study (Nagaya et al., 2014). 1, antipyrine; 2, carbamazepine; 3, lamotrigine; 4, ondansetron; 5, E2074; 6, risperidone; 7, verapamil; 8, paliperidone; 9, desloratadine; 10, quinidine.

**Figure 3.** Unbound plasma (solid line with circles) and CSF (dotted line with triangles) concentration-time profiles of antipyrine, ondansetron, desloratadine, and quinidine in cynomolgus

monkeys in the absence (open symbols) or presence (closed symbols) of concomitant intravenous administration of zosuquidar at 10 mg/kg. Zosuquidar and a cocktail of the test compounds were intravenously given to cynomolgus monkeys as described under Materials and Methods. Each point represents the mean  $\pm$  SD of three animals, except for the followings: plasma and CSF concentration of all test compounds at 2 h postdose in the presence of zosuquidar (mean of two animals due to convulsion observed in one of the three animals) and plasma concentration of antipyrine at 24 h postdose in the absence of zosuquidar (mean of two animals due to below quantification limit in one of the three animals).

**Figure 4.** Total plasma (closed circles), unbound plasma (gray circles), and CSF (open circles) concentration-time profiles of zosuquidar in cynomolgus monkey. The animal received two intravenous bolus doses of zosuquidar (both 10 mg/kg): immediately (10 min) before dosing the test compound cocktail and at 8 h later (indicated by arrows). Each point represents the mean  $\pm$  SD of three animals, except for 2 h postdose (mean of two animals due to convulsion observed in one of the three animals). The dashed and dotted lines show the simulated  $C_{\text{plasma}}$  and  $C_{\text{u,plasma}}$  of zosuquidar, respectively, based on the 2-compartment model analysis (Supplemental Figure 1).

**Figure 5.** Inhibitory effect of zosuquidar (0–1  $\mu\text{mol/L}$ ) on human P-gp-mediated transport of desloratadine (0.3  $\mu\text{mol/L}$ ) and quinidine (0.3  $\mu\text{mol/L}$ ). The data are shown as the percent of control as described in Materials and Methods. Each point represents the mean  $\pm$  SD of triplicate samples.

**Figure 6.** Comparison of  $K_{\text{p,uu,lumbar CSF}}$  of test compounds with the  $K_{\text{p,uu,ISF}}$  (A) and  $K_{\text{p,uu,cisternal CSF}}$  (B) in cynomolgus monkey. The  $K_{\text{p,uu,ISF}}$  and  $K_{\text{p,uu,cisternal CSF}}$  values are presented as the mean  $\pm$  SD

of three to five animals. The solid line passing through the origin represents the line of unity  $\pm$  3-fold (dashed lines). According to the previous report (Nagaya et al., 2014), the test compounds are classified into nonsubstrates (open circles: 1, antipyrine; 2, carbamazepine; 3, lamotrigine), weak substrates (gray circles: 4, ondansetron; 5, E2074) or good substrates of P-gp (closed circles: 6, risperidone; 7, verapamil; 8, paliperidone; 9, desloratadine; 10, quinidine) based on the in vitro CER values.

## Tables

**Table 1**  $K_{p,uu}$  values of test compounds in cynomolgus monkeys.

The  $K_{p,uu,lumbar\ CSF}$  values were compared with  $K_{p,uu,cisternal\ CSF}$  and  $K_{p,uu,ISF}$  values that were previously determined.

Test compounds	In vitro P-gp CER	AUC (ng·h/mL) <sup>b</sup>		$K_{p,uu,lumbar\ CSF}$ <sup>b</sup>	$K_{p,uu,cisternal\ CSF}$ <sup>a,c</sup>	$K_{p,uu,ISF}$ <sup>a,d</sup>	$K_{p,uu}$ ratio		
		Unbound plasma	Lumbar CSF				$\frac{Lumbar\ CSF}{Cisternal\ CSF}$	$\frac{Lumbar\ CSF}{ISF}$	$\frac{Cisternal\ CSF^a}{ISF}$
Antipyrine	1.0 <sup>a</sup>	1730 ± 699	1840 ± 692	1.10 ± 0.15	1.05	0.857	1.1	1.3	1.2
Carbamazepine	1.0 <sup>a</sup>	1170 ± 476	1560 ± 606	1.34 ± 0.10	1.19	1.27	1.2	1.1	0.94
Lamotrigine	1.1 <sup>a</sup>	15990 ± 1600	15700 ± 943	0.990 ± 0.066	0.875	0.678	1.1	1.5	1.3
Ondansetron	2.0 <sup>a</sup>	665 ± 118	570 ± 80	0.885 ± 0.259	0.481	0.483	1.8	1.8	1.0
E2074	2.2 <sup>a</sup>	244 ± 38	255 ± 41	1.05 ± 0.11	0.733	0.480	1.4	2.2	1.5
Risperidone	3.9 <sup>a</sup>	14.3 ± 3.7	6.59 ± 2.25	0.458 ± 0.074	0.133	0.126	3.4	3.6	1.1
Verapamil	5.4 <sup>a</sup>	306 ± 21	124 ± 14	0.406 ± 0.058	0.183	0.0789	2.2	5.1	2.3
Paliperidone	8.9 <sup>c</sup>	356 ± 166	73.7 ± 15.1	0.226 ± 0.061	0.0490	NT	4.6	NA	NA
Desloratadine	12 <sup>a</sup>	409 ± 3	79.7 ± 2.9	0.195 ± 0.006	0.129	0.0609	1.5	3.2	2.1
Quinidine	13 <sup>a</sup>	473 ± 66	132 ± 28	0.278 ± 0.029	0.169	0.0658	1.6	4.2	2.6

CER = corrected efflux ratio, NA = not applicable, NT = not tested.

<sup>a</sup>(Nagaya et al., 2014).

<sup>b</sup>Mean ± SD of three animals.

<sup>c</sup> $K_{p,uu,cisternal\ CSF}$  was the cisternal CSF-to-unbound plasma drug concentration ratio determined at steady state after intravenous infusion in cynomolgus monkeys.

<sup>d</sup> $K_{p,uu,ISF}$  was the ISF-to-unbound plasma drug concentration ratio determined at steady state after intravenous infusion in cynomolgus monkeys.

<sup>e</sup>Mean of triplicate determinations.




**Table 2**  $K_{p,uu,lumbar\ CSF}$  values of test compounds in the presence or absence of concomitant treatment with zosuquidar in cynomolgus monkeys

Test compounds	Unbound plasma AUC <sup>a</sup>		CSF AUC <sup>a</sup>		$K_{p,uu,lumbar\ CSF}$		$K_{p,uu,lumbar\ CSF}$ ratio
	Zosuquidar (-) <sup>b</sup>	Zosuquidar (+) <sup>c</sup>	Zosuquidar (-) <sup>b</sup>	Zosuquidar (+) <sup>c</sup>	Zosuquidar (-)	Zosuquidar (+) <sup>c</sup>	Zosuquidar (+)/(-)
Antipyrine	2980 ± 1180	2870 (3120, 2650)	3110 ± 1130	3080 (3290, 2870)	1.05 ± 0.04	1.07 (1.05, 1.08)	1.0
Ondansetron	586 ± 180	508 (752, 484)	493 ± 110	653 (728, 578)	0.861 ± 0.096	1.08 (0.968, 1.19)	1.3
Desloratadine	515 ± 39	587 (619, 692)	77.0 ± 8.5	163 (164, 163)	0.151 ± 0.026	0.250 (0.264, 0.235)	1.7
Quinidine	483 ± 181	363 (515, 332)	114 ± 39	412 (472, 351)	0.239 ± 0.011	0.987 (0.916, 1.06)	4.1

<sup>a</sup>Unit, ng·h/mL.<sup>b</sup>Mean ± SD of three animals.<sup>c</sup>Mean of two animals with individual values in the parenthesis.

Figure 1



**Figure 2**






Figure 3


Antipyrine



Ondansetron



Desloratadine



Quinidine




Figure 4





Figure 5

### Desloratadine



### Quinidine






Figure 6



[Title] Impact of P-glycoprotein-mediated active efflux on drug distribution into lumbar cerebrospinal fluid in nonhuman primates

[Authors] Yoko Nagaya, Kazuhide Katayama, Hiroyuki Kusuhara, Yoshitane Nozaki

[Journal] Drug Metabolism and Disposition

[Manuscript number] DMD-AR-2020-000099

### Supplemental Table 1. Efflux ratio and % of control in in vitro P-gp inhibition study

The efflux ratio (ER) was calculated for desloratadine and quinidine from the ratio of the apparent permeability ( $P_{app}$ ) in basal-to-apical direction ( $P_{app,B-A}$ ) to that in apical-to-basal direction ( $P_{app,A-B}$ ) in the P-gp-expressing cells ( $ER_{P-gp}$ ) and control cells ( $ER_{Ctrl}$ ). The percentage of control values for P-gp-mediated transcellular transport ( $ER_{P-gp} - ER_{Ctrl}$ ) of desloratadine and quinidine in the presence of zosuquidar were calculated from the ER values as described in Materials and Methods.

#### (A) Desloratadine

Zosuquidar ( $\mu\text{mol/L}$ )	P-gp-expressing LLC-PK1 cells			Control LLC-PK1 cells			$ER_{P-gp} - ER_{Ctrl}$	% of control
	$P_{app,A-B}$	$P_{app,B-A}$	$ER_{P-gp}$	$P_{app,A-B}$	$P_{app,B-A}$	$ER_{Ctrl}$		
	( $\times 10^{-6} \text{ cm/sec}$ )	( $\times 10^{-6} \text{ cm/sec}$ )		( $\times 10^{-6} \text{ cm/sec}$ )	( $\times 10^{-6} \text{ cm/sec}$ )			
0	2.44 ± 0.01	31.65 ± 0.80	12.97 ± 0.33	10.97 ± 0.40	11.75 ± 0.27	1.07 ± 0.05	11.90 ± 0.39	100.0 ± 4.3
0.0001	2.65 ± 0.15	29.12 ± 0.96	10.99 ± 0.71	10.20 ± 0.91	10.66 ± 0.51	1.05 ± 0.11	9.94 ± 0.91	83.5 ± 8.5
0.001	3.03 ± 0.15	28.47 ± 1.04	9.40 ± 0.59	10.65 ± 0.88	10.66 ± 0.52	1.00 ± 0.10	8.40 ± 0.87	70.6 ± 6.8
0.003	4.60 ± 0.58	27.89 ± 0.47	6.06 ± 0.77	12.52 ± 0.38	10.99 ± 0.38	0.88 ± 0.04	5.18 ± 0.38	43.5 ± 2.0
0.01	6.62 ± 0.39	25.52 ± 0.51	3.85 ± 0.24	11.36 ± 0.29	10.41 ± 0.22	0.92 ± 0.03	2.93 ± 0.29	24.6 ± 0.8
0.03	9.99 ± 0.83	18.04 ± 0.38	1.81 ± 0.15	11.15 ± 0.86	10.10 ± 0.59	0.91 ± 0.09	0.90 ± 0.85	7.6 ± 0.7
0.1	12.42 ± 0.57	13.65 ± 0.40	1.10 ± 0.06	11.89 ± 1.11	9.63 ± 0.07	0.81 ± 0.08	0.29 ± 1.11	2.4 ± 0.2
1	16.63 ± 1.50	15.59 ± 0.52	0.94 ± 0.09	12.76 ± 1.13	13.15 ± 0.54	1.03 ± 0.10	-0.09 ± 1.13	-0.8 ± 0.1 <sup>a</sup>

a: Handled as zero when estimating the  $IC_{50}$  value by least-squares nonlinear regression analysis.



## (B) Quinidine

Zosuquidar ( $\mu\text{mol/L}$ )	P-gp-expressing LLC-PK1 cells			Control LLC-PK1 cells			ER <sub>P-gp</sub> -ER <sub>Ctrl</sub>	% of control
	P <sub>app,A-B</sub> ( $\times 10^{-6}$ cm/sec)	P <sub>app,B-A</sub> ( $\times 10^{-6}$ cm/sec)	ER <sub>P-gp</sub>	P <sub>app,A-B</sub> ( $\times 10^{-6}$ cm/sec)	P <sub>app,B-A</sub> ( $\times 10^{-6}$ cm/sec)	ER <sub>Ctrl</sub>		
0	2.70 $\pm$ 0.60	39.52 $\pm$ 3.26	14.64 $\pm$ 3.26	15.86 $\pm$ 0.46	18.05 $\pm$ 0.54	1.14 $\pm$ 0.05	13.50 $\pm$ 0.6	100.0 $\pm$ 4.2
0.0001	1.88 $\pm$ 0.24	38.04 $\pm$ 2.59	20.23 $\pm$ 2.59	14.07 $\pm$ 1.35	16.91 $\pm$ 0.27	1.20 $\pm$ 0.12	19.03 $\pm$ 1.35	141.0 $\pm$ 13.8
0.001	2.18 $\pm$ 0.26	36.49 $\pm$ 2.01	16.74 $\pm$ 2.01	14.92 $\pm$ 0.80	16.80 $\pm$ 0.14	1.13 $\pm$ 0.06	15.61 $\pm$ 0.80	115.6 $\pm$ 6.3
0.003	2.98 $\pm$ 0.32	37.31 $\pm$ 1.36	12.52 $\pm$ 1.36	17.73 $\pm$ 0.75	17.67 $\pm$ 0.23	1.00 $\pm$ 0.04	11.52 $\pm$ 0.75	85.3 $\pm$ 3.8
0.01	4.25 $\pm$ 0.30	36.98 $\pm$ 0.63	8.70 $\pm$ 0.63	15.83 $\pm$ 0.28	16.39 $\pm$ 0.45	1.04 $\pm$ 0.03	7.66 $\pm$ 0.28	56.7 $\pm$ 1.9
0.03	8.23 $\pm$ 0.64	31.23 $\pm$ 0.30	3.79 $\pm$ 0.30	15.87 $\pm$ 0.25	16.07 $\pm$ 0.56	1.01 $\pm$ 0.04	2.78 $\pm$ 0.25	20.6 $\pm$ 0.8
0.1	16.96 $\pm$ 0.44	22.50 $\pm$ 0.04	1.33 $\pm$ 0.04	16.70 $\pm$ 0.45	15.81 $\pm$ 0.27	0.95 $\pm$ 0.03	0.38 $\pm$ 0.45	2.8 $\pm$ 0.1
1	23.38 $\pm$ 0.30	21.29 $\pm$ 0.03	0.91 $\pm$ 0.03	19.26 $\pm$ 0.63	18.39 $\pm$ 0.23	0.95 $\pm$ 0.03	-0.04 $\pm$ 0.63	-0.3 $\pm$ 0.0 <sup>a</sup>


a: Handled as zero when estimating the IC<sub>50</sub> value by least-squares nonlinear regression analysis.

[Title] Impact of P-glycoprotein-mediated active efflux on drug distribution into lumbar cerebrospinal fluid in nonhuman primates

[Authors] Yoko Nagaya, Kazuhide Katayama, Hiroyuki Kusuhara, Yoshitane Nozaki

[Journal] Drug Metabolism and Disposition

[Manuscript number] DMD-AR-2020-000099



**Supplemental Figure 1. Plasma concentration-time profile of zosuquidar in monkey after a single intravenous administration**

One male cynomolgus monkey (4 years old, 4 kg) was used. A single intravenous bolus dose of zosuquidar (10 mg/kg) was given to monkey via the saphenous vein to measure the drug concentrations in plasma. Blood samples (0.5 mL per sampling point) were collected using heparinized syringes via the cephalic vein at 5, 15, 30 minutes, and 1, 2, 4, 6, 8, and 24 hours after dosing. The blood samples were centrifuged to prepare plasma. The plasma samples were stored below  $-20^{\circ}\text{C}$  until analysis. Closed circles represent observed total plasma concentrations and the solid line represents the fitted curve that was obtained by 2-compartment model with a weighting factor 2 using Phoenix WinNonlin Ver8.1 (Certara USA Inc., Princeton, NJ). The plasma concentration was described as follows:

$$C_{\text{plasma}} = A \times e^{-\alpha t} + B \times e^{-\beta t}$$

The A,  $\alpha$ , B, and  $\beta$  were estimated to be 1950 ng/mL,  $0.525 \text{ h}^{-1}$ , 303 ng/mL, and  $0.103 \text{ h}^{-1}$ , respectively.

[Title] Impact of P-glycoprotein-mediated active efflux on drug distribution into lumbar cerebrospinal fluid in nonhuman primates

[Authors] Yoko Nagaya, Kazuhide Katayama, Hiroyuki Kusuhara, Yoshitane Nozaki

[Journal] Drug Metabolism and Disposition

[Manuscript number] DMD-AR-2020-000099

**Supplemental Table 2. Comparison of  $K_{p,uu,lumbar\ CSF}$  values with  $C_{CSF}/C_{u,plasma}$  at 24 hours after starting infusion**

The  $K_{p,uu,lumbar\ CSF}$  values were compared with the  $C_{CSF}$ -to- $C_{u,plasma}$  ratios ( $C_{CSF}/C_{u,plasma}$ ) at 24 hours after starting infusion in animal study Part 1 (A) and Part 2 (B). The correlation is graphically shown in (C). The  $K_{p,uu,lumbar\ CSF}$  values were obtained from Table 1 or Table 2.

(A) Part 1

Test compounds	$K_{p,uu,lumbar\ CSF}$	$C_{CSF}/C_{u,plasma}$ at 24 h	Fold difference
Antipyrine	1.10 ± 0.15	0.924 ± 0.323	1.2
Carbamazepine	1.34 ± 0.10	1.87 ± 1.07	0.7
Lamotrigine	0.990 ± 0.066	1.06 ± 0.07	0.9
Ondansetron	0.885 ± 0.259	0.784 ± 0.350	1.1
E2074	1.05 ± 0.11	1.01 ± 0.76	1.0
Risperidone	0.458 ± 0.074	0.206 <sup>a</sup>	2.2
Verapamil	0.406 ± 0.058	0.266 ± 0.158	1.5
Paliperidone	0.226 ± 0.061	0.258 ± 0.100	0.9
Desloratadine	0.195 ± 0.006	0.227 ± 0.066	0.9
Quinidine	0.278 ± 0.029	0.194 ± 0.052	1.4

<sup>a</sup>Data from single animal because the  $C_{CSF}$  at 24 hours was below the quantification limit (< 0.1 ng/mL) in two out of three animals.

$K_{p,uu,lumbar\ CSF}$  and  $C_{csf}/C_{u,plasma}$  at 24 h are represented as mean ± SD.

(B) Part 2 (with and without zosuquidar co-treatment)

Test compounds	Zosuquidar (-)			Zosuquidar (+)		
	$K_{p,uu,lumbar\ CSF}^a$	$C_{CSF}/C_{u,plasma}$ at 24 h <sup>a</sup>	Fold difference	$K_{p,uu,lumbar\ CSF}^b$	$C_{CSF}/C_{u,plasma}$ at 24 h <sup>a</sup>	Fold difference
Antipyrine	1.05 ± 0.04	1.11 ± 0.19	1.0	1.07 (1.05, 1.08)	1.04 ± 0.16	1.0
Ondansetron	0.861 ± 0.096	0.422 ± 0.156	2.0	1.08 (0.968, 1.19)	0.880 ± 0.297*	1.2
Desloratadine	0.151 ± 0.026	0.144 ± 0.026	1.0	0.250 (0.264, 0.235)	0.268 ± 0.087	0.9
Quinidine	0.239 ± 0.011	0.271 ± 0.153	0.9	0.987 (0.916, 1.06)	1.57 ± 0.86**	0.6

<sup>a</sup>Mean ± SD of three animals.

<sup>b</sup>Mean of two animals with individual values given in the parenthesis.

\*:  $P < 0.05$ , \*\*:  $P < 0.01$  (Paired  $t$  test vs Zosuquidar (-))

(C) Correlation

